Eli Lilly Reports post-marketing Data for Ribociclib in Cervical cancer

Eli Lilly today announced post-marketing results for ribociclib in patients with cervical cancer. The study demonstrated that ribociclib achieves clinical remission compared to standard of care or placebo. These results provide important insights into the treatment of cervical cancer and support the continued development of ribociclib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.